Responses
Clinical/translational cancer immunotherapy
Original research
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
